[go: up one dir, main page]

CN102816126A - Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof - Google Patents

Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof Download PDF

Info

Publication number
CN102816126A
CN102816126A CN2011101500699A CN201110150069A CN102816126A CN 102816126 A CN102816126 A CN 102816126A CN 2011101500699 A CN2011101500699 A CN 2011101500699A CN 201110150069 A CN201110150069 A CN 201110150069A CN 102816126 A CN102816126 A CN 102816126A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101500699A
Other languages
Chinese (zh)
Inventor
徐进宜
姚和权
刘琴
吴晓明
孙飞
蒋婧章
赵金会
陆冬
王秋娟
纪海霞
傅蓉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN2011101500699A priority Critical patent/CN102816126A/en
Publication of CN102816126A publication Critical patent/CN102816126A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to the field of pharmaceutical chemistry, and specifically relates to a preparation method of sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity. According to the invention, R1, R2, R3, and R4 are defined as in the specifications. The invention also relates to medical applications of the derivatives, especially the applications of the derivatives as medicines used for resisting hypertension and having cardiovascular protective effects.

Description

The substituted triazole class verivate of amine sulphonyl aryl, Preparation Method And The Use with cardiac vascular activity
Figure BSA00000511130100011
Technical field
The present invention relates to the pharmaceutical chemistry field; The substituted triazole class verivate of amine sulphonyl aryl that to be specifically related to one type of biphenyl be skeleton, pharmaceutical composition and the said compound that the invention also discloses the preparation method of this analog derivative and contain said compound is in treatment hypertension, congestive heart failure and through exciting Angiotensin II (AT 2) acceptor treats the application in other disease or the illness.
Background technology
RAS (RAS) plays an important role in blood pressure regulation and body fluid, electrolyte balance.(angiotensinII is a kind of important multi-functional vaso-active substance among the RAS AngII) to Angiotensin II, has confirmed that Ang II is directly through two kinds of different receptor subtype AT in the human body 1And AT 2Acceptor plays a role.AT 1Receptor-mediated most physiological functions are like vasoconstriction, increase water-sodium retention etc.AngII and AT 2(nitric oxide NO)/the cGMP cascade reaction, produces cardiovascular provide protection to activate kallidin-9/nitrogen protoxide after the receptors bind.
II Angiotensin II AT 1Receptor antagonist exposes some untoward reactions gradually in lots of clinical is used, but such medicine is still antihypertensive drug and the anti-heart failure medicine that has than the big market potentiality.AT 2Receptor stimulant is known as " AT 1The acceptor natural agonist ", AT 1Receptor antagonist and AT 1After the receptors bind, promote AngII and AT 2Receptors bind activates AT 2Acceptor.AT 2Acceptor more and more receives publicity as a potential drug target.Research shows II Angiotensin II AT 2Receptor stimulant can improve the whole structure of hypertension therapeutic, improves health level, and such medicine might become II Angiotensin II AT 1The natural partner of receptor antagonist is called as the depressor of New Times.
This seminar basis is both at home and abroad to selectivity AT 2The latest report of receptor stimulant [1-5]In conjunction with existing structure activity relationship information; Selection is basic framework with biphenyl, and parent heterocycle structure and substituting group thereof are carried out structure of modification, and design has been synthesized a series of new substituted triazole class verivates of amine sulphonyl aryl (referring to 1.Carey R M.Current Opinion inNephrology & Hypertension; 2005,14 (1): 67-71; 2.Wan Y, Wallinder C, Plouffe B, et al.JMed Chem, 2004,47 (24): 5995-6008; 3.Wu X, Wan Y, Mahalingam A K, et al.J MedChem, 2006,49 (24): 7160-7168; 4.Murugaiah A M S, Wallinder C, Mahalingam A K, et al.Bioorg Med Chem, 2007,15 (22): 7166-7183; 5.Wallinder C, Botros M, U, et al.Bioorg Med Chem, 2008,16 (14): 6841-6849.).
Summary of the invention
The AT that has the selectivity cardiac vascular activity for searching 2The receptor stimulant kind new medicine; The present invention found substituting group 4 '-[1-(3-replacement-1H-1; 2, the 4-triazole) methyl]-5-substituted biphenyl-2-sulfoamido carboxylicesters or N-4 '-[1-(3-replacement-1H-1,2; The 4-triazole) methyl]-new compound of 5-isobutyl-biphenyl-2-alkylsulfonyl alkylamide class formation, thus a series of verivates with general formula (I) structural performance are provided.General formula (I) has been expanded existing AT 2The constitutional features of receptor stimulant medicine and range of structures.
The technical problem that the present invention will solve is the AT that has of research new texture type 2The compound of receptor agonist activity, and a kind of pharmaceutical composition of treating hypertension, congestive heart failure and other disease or illness further is provided.Another object of the present invention provides above-mentioned medicinal compsns and passes through exciting AT in preparation 2Acceptor is treated the purposes of the medicine aspect of other disease or illness.
For solving the problems of the technologies described above, the present invention provides following technical scheme:
The compound or pharmaceutically acceptable salt thereof of general formula (I):
Figure BSA00000511130100022
R wherein 1Represent hydrogen, alkoxyl group, carboxyl, carbalkoxy, ester group;
R 2Represent hydrogen, C 1-C 6The alkyl of straight or branched, C 2-C 6The alkenyl of straight or branched, C 2-C 6The alkynyl of straight or branched, C 1-C 6The alkoxyl group of straight or branched, phenyl, fragrant heterocycle perhaps replace fragrant heterocycle, and said replacement heterocyclic base can be chosen wantonly from one or more C of being selected from 1-C 6Alkyl, C 1-C 6Alkoxy or halogen replaces, and each substituting group is identical or different;
R 3Represent hydrogen, C 1-C 4Alkyl or halogen;
R 4Represent hydrogen, C 1-C 4Alkyl or alkoxyl group;
Ar represents phenyl or fragrant heterocycle, and said fragrant heterocycle refers to 1-2 the fragrant heterocycle of heteroatomic 5-6 unit, and said heteroatoms independently is selected from O, S or N separately.
What the compound or pharmaceutically acceptable salt thereof of general formula (I) was even more ideal is: R wherein 1Be hydrogen, carbalkoxy or ester group; R 2Be C 1-C 4Straight chained alkyl or C 1-C 4The straight chain alkoxyl group; R 3Represent hydrogen or halogen, R 4Represent hydrogen; Ar represents phenyl ring, pyrroles or thiphene ring.
The present invention includes a kind of Mammals that is used to treat, be preferable over the pharmaceutical composition of treatment human diseases or illness, it comprises treatment hypertension, congestive heart failure, myocardial hypertrophy, vasospasm and passes through exciting AT 2Acceptor is treated compound or its salt and pharmaceutically acceptable carrier of the general formula (I) of the significant quantity of other disease or illness.
The present invention comprises that also the compound or its salt of general formula (I) is preparing treatment hypertension, congestive heart failure, myocardial hypertrophy, vasospasm and passing through exciting AT 2Acceptor is treated the application in the medicine of other illness.
Reaction 1
Figure BSA00000511130100031
Reaction 2
Figure BSA00000511130100032
Reaction 3
Figure BSA00000511130100033
Reaction 4
With reference to reaction scheme 1, substituted 1,2,4-triazole (1) and bromine bromobenzyl (2) mixed, in the alkaline medium, preferred salt of wormwood, backflow 12h, through filtering, acidifying, preferred hydrochloric acid filters, and solid chemical compound alkalizes again, makes corresponding formula (3) compound.
With reference to reaction scheme 2, formula (4) compound is added in the chloroform, drip chlorsulfonic acid in 0-5 ℃ and react, after dripping; In room temperature refluxed 3-5h, reaction solution is slowly added in the trash ice, layering, water layer is used ethyl acetate extraction; Make corresponding formula (5) compound, formula (5) compound is dissolved in the methylene dichloride, add triethylamine; Drip TERTIARY BUTYL AMINE, room temperature reaction 8-12h makes corresponding formula (6) compound.
Formula (6) compound is dissolved in the THF, in below-78 ℃, drips n-Butyl Lithium ,-20 ℃ are stirred 12-18h, add acid, get corresponding formula (7) compound.
With formula (3) compound and formula (7) compound and toluene, mix in the ethanol, add palladium, triphenylphosphine, in basic soln, backflow 5-6h adds water, continues reaction 3-5h, gets corresponding formula (8) compound.
Formula (8) compound is dissolved in the methylene dichloride, adds trifluoracetic acid, react 12h under the room temperature, get formula (9) compound.
Formula (9) compound is dissolved in the methylene dichloride, and adding formula (10) compound reacts 1-3h under the room temperature, gets formula (I) title product.
Below be the pharmacology test and the data of part of compounds of the present invention, the structure that the compound code name is corresponding in the pharmacological testing is seen embodiment.
On preliminary basis, select sample embodiment 12,13 and further study as the trial-product group to the prerun of trial-product group; With male spontaneous hypertensive rat (SHR) sample is screened, every treated animal quantity is 8.
Blank group (giving equivalent saline water);
Each treated animal adopts oral administration, and dosage is 20mg/kg, and the medicine liquid irrigation stomach is preceding with 37 ℃ of water temperature heat, administration volume 0.8ml/100g.
Blood pressure (SAP, DAP, MAP) and heart rate (HR) result that each treated animal is measured all represent with
Figure BSA00000511130100042
± s, carries out (pairing) before and after the self administration and reach and the t-test statistics processing of blank group between organizing.
The acute reduced pressure experiment of 12,13 pairs of anesthesia of compound SHR rat
Figure BSA00000511130100051
Annotate: 1.*:P＜0.1; *: P＜0.05; Compare with control group * *: P＜0.01.
2. blood pressure (heart rate) before blood pressure (heart rate)-administration after blood pressure (heart rate) absolute change value (Δ)=administration
The result finds that compound 12 has tangible hypotensive effect suitable with the positive drug losartan; Compound 13 has hypotensive activity preferably, and its antihypertensive effect is near the positive drug losartan, and the two compares difference to the heart rate of anesthesia SHR with control group do not have significance meaning (P＞0105), has further researching value.
Embodiment
Embodiment 1
1-(4-bromobenzyl)-1H-1,2, the 4-triazole
With triazole (2.011g, 0.029mol), (1.022g 7.341mmol) joins in the eggplant-shape bottle of 50ml salt of wormwood successively, adds solvent THF (30ml); Stir 10min, (3.691g 0.015mol) is dissolved among the DMF (5ml), is added dropwise in the reaction solution to the bromine bromobenzyl; Be warming up to backflow after dropwising, react about 15h, suction filtration, concentrating under reduced pressure; Add 15ml water, the adularescent solid is separated out, and suction filtration gets white solid 2.374g, yield: 68.9%. 1HNMR(CDCl 3，300MHz)：δ(ppm)5.307(2H，s，CH 2)，7.144(each?1H，d，J＝8.4Hz，CH 2-Ar)，7.511(each?1H，d，J＝8.4Hz，CH 2-Ar)，7.498(1H，s，3H)，8.098(1H，s，4H)；EI-MS，m/z：237，M：[M+2]＝1∶1.
Embodiment 2
4-isobutyl-benzene SULPHURYL CHLORIDE
(3.421g 0.0255mol) is dissolved in imitative chlorine (30ml), drops in the three-necked bottle of 100ml with isobutyl-benzene; After under cryosel is bathed, stirring 10min, (11.815g 0.102mol) is added dropwise in the reaction flask chlorsulfonic acid; Drip off in the 45-60min, the dropping process keeps temperature to be no more than 5 ℃.At room temperature react 45min after dripping.Reaction solution is poured in the trash ice, and standing demix takes out organic layer, and water layer is used CH 2Cl 2Extraction (20ml * 2) merges organic layer, saturated NaHCO 3Solution is washed (30ml * 2), saturated nacl aqueous solution washing organic layer (30ml * 2), anhydrous MgSO 4Drying, suction filtration, filtrate decompression concentrate faint yellow oily thing (42) 2.264g, yield: 38.2%.
Embodiment 3
The N-tertiary butyl-4-isobutyl-benzene sulphonamide
(3.232g 0.0139mol) adds in the eggplant-shape bottle of 50ml, adds CH with 4-isobutyl-benzene SULPHURYL CHLORIDE 2Cl 2(30ml), triethylamine (1.547g, 0.0153mol), stir 10min after, begin to drip TERTIARY BUTYL AMINE (1.220g, 0.0167mol).Behind the reaction 8h, suction filtration is filtrated and is washed (25ml * 3) under the room temperature, saturated nacl aqueous solution washing organic layer (30ml * 2), anhydrous Na S0 4Dried overnight, suction filtration, filtrate decompression concentrate 3.157g white solid (43), yield: 79.0%.
Embodiment 4
2-(N-tertiary butyl sulfamyl)-5-isobutyl-benzene boric acid
The N-tertiary butyl-4-isobutyl-benzene sulphonamide is joined in the three-necked bottle of 150ml, add anhydrous THF (35ml), vacuumize N in the bottle 2Protection.The external application liquid nitrogen cooling is to-78 ℃, begin to drip n-Butyl Lithium (2.5M/L, 0.0293mol); Temperature maintenance is at-80 ℃～-75 ℃ in the dropping process; Dropwise the back holding temperature at-20 ℃ of reaction 4h, be cooled to-78 ℃, drip triisopropyl borate ester (3.301g; 0.0176mol), rise to room temperature reaction and spend the night.Add 2M HCl and be slightly acidic to reaction solution, standing demix, organic layer is continued to employ, and water layer merges organic layer with EtOAc extraction (20ml * 2), concentrating under reduced pressure, column chromatography (sherwood oil: ETHYLE ACETATE=5: 1) get faint yellow oily thing 2.060g, yield: 56.3%.
1HNMR(CDCl 3，300MHz)：δ(ppm)0.863(6H，d，J＝6.6Hz)，1.079(9H，s，t-Bu)，1.858(1H，m，CH)，6.825(1H，s，NH)，7.271(1H，d，J＝4.2Hz，H-4)，7.381(1H，s，H-6)，7.721(1H，d，J＝7.8Hz，H-3)，8.356(2H，s，B(OH) 2).
Embodiment 5
4 '-[(1H-1,2,4-triazole-1-yl) the methyl]-N-tertiary butyl-5-isobutyl--2-biphenyl sulphonyl ammonia
In the 100ml three-necked bottle, add 2-(N-tertiary butyl sulfamyl)-4-isobutyl-benzene ylboronic acid (0.799g, 2.55mmol), 1-(4-bromobenzyl)-1H-1,2, the 4-triazole (0.620g, 2.55mmol); Toluene (15ml), and NaOH (1.56M, 7ml), ethanol (12ml), the adding palladium (14mg, 0.05mmol); Triphenylphosphine (55mg, 0.204mmol), logical nitrogen protection, reflux 5h, stopped reaction; Remove nitrogen, be cooled to room temperature, add water 20ml standing demix, organic layer is continued to employ, and water layer uses ETHYLE ACETATE (20ml * 3) to extract again; Merge organic layer, saturated nacl aqueous solution washing organic layer, anhydrous magnesium sulfate drying concentrates column chromatography (CH 2Cl 2: CH 3OH=80: 1) get faint yellow oily thing 0.940g, yield: 86.6%.
1HNMR(CDCl 3，300MHz)：δ(ppm)0.905(6H，d，J＝6.6Hz)，0.987(9H，s)，1.897(1H，m)，2.535(2H，d，J＝7.2Hz)，3.515(1H，s，NH)，7.048(1H，d，J＝1.5Hz，H-4)，7.238(1H，d，J＝0.9Hz，H-6)，7.343(each?1H，d，J＝4.2Hz，CH 2-Ar)，7.529(each?1H，d，J＝8.1Hz，CH 2-Ar)，7.995(1H，s，3H)，8.051(1H，d，J＝8.1Hz，H-3)，8.149(1H，s，4H).
Embodiment 6
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl--2-sulphonyl ammonia
With 4 '-[1-(1H-1,2,4-triazole) the methyl]-N-tertiary butyl-5-isobutyl--2-sulfamyl biphenyl (1.130g; 0.00265mol) join in the 25ml eggplant-shape bottle, add TFA (4ml), stir; After reacting 12h under the room temperature; Concentrating under reduced pressure is removed most of TFA, ETHYLE ACETATE (15ml) dissolving, saturated NaHCO 3The washing organic layer, anhydrous Na SO 4Dried overnight, suction filtration, filtrate decompression concentrates, column chromatography (CH 2Cl 2: CH 3OH=80: 1) get faint yellow solid 0.536g, yield: 54.6%.
ESI-MS，m/z：369[(M-H) -]，371[(M+H) +].
Embodiment 7
N-{4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-alkylsulfonyl } propionic acid amide
With 4 '-[1-(1H-1,2,4-triazole) methyl]-(0.197g 0.510mmol) joins in the 25ml eggplant-shape bottle 5-isobutyl--2-biphenyl sulfonamide, adds anhydrous CHCl 3(4ml), add triethylamine (0.1ml), ice bath adds propionyl chloride (0.1ml) after stirring 10min down, under the room temperature behind the reaction 3h, and concentrating under reduced pressure, column chromatography (CH 2Cl 2: CH 3OH=80: 1) get white solid 62.7mg.Productive rate: 28.9%.mp?144-146℃。
IR(film，cm -1)：2957，2926，2024，1704，1467，1333，1141；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.818(6H，d，J＝5.1Hz，( CH 3) 2CH)，0.905(3H，t，J＝5.1Hz，CH 3)，2.008(2H，q，J＝7.5，15Hz，CH 2)，1.830～1.972(1H，m，(CH 3) 2 CH)，2.542(2H，d，J＝6.9Hz， CH 2CH)，5.438(s，2H，CH 2)，7.039(1H，d，J＝1.2Hz)，7.337(4H，dd，J＝3.9，2.7Hz)，7.998(1H，s)，8.195(2H，d，J＝8.1Hz)，8.292(1H，s)；
ESI-MS，m/z：425[(M-H) -]，427[(M+H) +].
Embodiment 8
N-{4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-alkylsulfonyl } valeramide
Preparing method with reference to embodiment 7.Productive rate: 31.5%.mp?100-102℃。
IR(film，cm -1)：3439，2957，2024，1717，1336，1138；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.885(3H，t，J＝6.9Hz，CH 3)，0.942(6H，d，J＝6.6Hz，( CH 3) 2CH)，1.452～1.477(m，2H，CH 3 CH 2)，1.879～1.961(4H，m)，1.187～1.211(1H，m，(CH 3) 2 CH)，2.539(2H，d，J＝6.0Hz，CH 2CO)，5.435(2H，s)，7.038(1H，s)，7.232～7.358(m，5H)，7.965(1H，s)，8.199(1H，dd，J＝1.5，6.6Hz)，8.248(1H，s)；
ESI-MS，m/z：453.3[(M-H) -]，455[(M+H) +].
Embodiment 9
N-{4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-alkylsulfonyl }-the 4-monomethylaniline
With 4 '-[(1H-1,2,4-triazole-1-yl) methyl]-(0.197g 0.510mmol) joins in the 25ml eggplant-shape bottle 5-isobutyl--2-sulphonyl ammonia, adds anhydrous CHCl 3(4ml), add triethylamine (0.1ml), after ice bath stirs 10min down, homemade Tosyl chloride is added dropwise to is dissolved in anhydrous CHCl 3Be added dropwise in the reaction flask, under the room temperature reaction 3h after, concentrating under reduced pressure, column chromatography (CH 2Cl 2: CH 3OH=80: 1) get white solid 30mg.Productive rate: 12.1%.mp?100～102℃。
IR(film，cm -1)：3438，2956，2024，1752，1607，1228，1163；ESI-MS，m/z：487.2[(M-H) -].
Embodiment 10
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-sulfoamido ethyl formate
With 4 '-[(1H-1,2,4-triazole-1-yl) methyl]-(0.311g 0.807mmol) is dissolved in anhydrous pyridine (4ml) to 5-isobutyl--2-sulphonyl ammonia; After ice bath stirs 10min down, and the adding Vinyl chloroformate (0.193ml, 2.021mmol), after ice bath reacts 4h down; Add water, ethyl acetate extraction merges organic layer; 1M HCl washs organic layer (20ml * 3), and saturated nacl aqueous solution is washed, column chromatography (CH 2Cl 2: CH 3OH=80: 1) get white solid 0.197g.Productive rate: 55.2%.mp96-98℃。
IR(film，cm -1)：3415，2957，2025，1744，1340，1161，1144，576；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.844(6H，d，J＝6.6Hz，( CH 3) 2CH)，1.064(3H，t，J＝6.9Hz， CH 3CH 2)，1.785～1.874(1H，m，(CH 3) 2 CH)，2.476(2H，d，J＝7.2Hz，CH 2 CH)，4.014(2H，q，J＝7.2，7.2Hz， CH 2CH 3)，5.300(2H，s， CH 2CH)，6.978(1H，d，J＝1.5Hz)，7.148(2H，d，J＝8.1Hz)，7.240～7.288(m，3H)，7.853(1H，s)，8.039(s，1H)，8.103(1H，d，J＝8.1Hz)，8.473(1H，s)；ESI-MS，m/z：442[(M-H) -].
Embodiment 11
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-base biphenyl-2-sulfoamido t-butyl formate
With 4 '-[(1H-1,2,4-triazole-1-yl) methyl]-(0.180g 0.486mmol) is dissolved in anhydrous CH to 5-isobutyl--2-sulphonyl ammonia 2Cl 2(4ml), add triethylamine (0.1ml), ice bath adds (Boc) after stirring 10min down 2O (0.127g, 0.584mmol), under the room temperature reaction 6h after, concentrating under reduced pressure, column chromatography (CH 2Cl 2: CH 3OH=80: 1) get white solid 0.103g.Productive rate: 45.2%.mp?97-100℃。
IR(film，cm -1)：3418，2958，2925，2024，1739，1515，1341，1139；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.844(6H，d，J＝6.6Hz)，1.229(9H，s，t-Bu)，1.773～1.811(m，1H)，2.486(2H，d，J＝7.2Hz)，5.330(2H，s)，6.993(1H，s)，1.171(1H，s)，7.199(2H，d，J＝2.4Hz)，7.273(1H，d，J＝3.0Hz)，7.315(2H，d，J＝6.3Hz)，7.892(1H，s)，8.058(1H，s)，8.084(1H，s)；ESI-MS，m/z：469.3[(M-H) -].
Embodiment 12
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-sulfoamido butyl formate
Preparing method with reference to embodiment 10.Yield: 40.9%.mp?78-80℃。
IR(film，cm -1)：3417，2958，2930，2024，1743，1510，1342，1160，1144；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.767(3H，t，J＝7.5Hz，CH 3)，0.842(6H，d，J＝6.6Hz)，1.335～1.350(2H，m，CH 3 CH 2)，1.809～2.022(1H，m)，2.480(2H，d，J＝7.2Hz， CH 2CH)，3.948(2H，t，J＝6.6Hz，CH 2O)，5.342(s，2H)，6.993(1H，d，J＝1.5Hz)，7.117(1H，s)，7.217～7.299(5H，m)，7.918(1H，s)，8.074(1H，s)，8.095(1H，d，J＝3.6Hz)；
ESI-MS，m/z：469.3[(M-H) -].
Embodiment 13
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-sulfoamido benzyl formate
Preparing method with reference to embodiment 10.Yield: 31.1%.mp?100-102℃。
IR(film，cm -1)：3419，3033，2957，2926，2025，1745，1510，1342，1160，1144；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.895(2H，d，J＝8.4Hz)，1.854～1.944(m，1H)，2.546(2H，d，J＝7.2Hz)，5.022(2H，s，CH 2O)，5.327(2H，s，CH 2)，6.998(1H，s)，7.111～7.198(m，5H)，7.307～7.328(m，3H)，7.730(1H，s)，8.126(1H，s)，8.166(2H，d，J＝7.5Hz)；
ESI-MS，m/z：503[(M-H) -].
Embodiment 14
4-isobutyl-benzene SULPHURYL CHLORIDE
With reference to the preparation method of embodiment 2, get faint yellow oily thing, yield: 42.0%.
Embodiment 15
The N-tertiary butyl-4-isobutyl-benzene sulphonamide
With reference to the preparation method of embodiment 3, get white solid, yield: 83.5%.
Embodiment 16
2-(N-tertiary butyl sulfamyl)-5-methoxyphenylboronic acid
With reference to the preparation method of embodiment 4, get faint yellow oily thing, yield: 56.1%.
1HNMR(CDCl 3，300MHz)：δ(ppm)1.184(9H，s)，3.384(3H，s，CH 3O)，4.675(1H，s，NH)，5.963(2H，s，B(OH) 2)，6.960(1H，d，J＝6.3Hz，H-4)，7.368(1H，s，H-6)，7.970(1H，d，J＝10.5Hz，H-3).
Embodiment 17
4 '-[1-(1H-1,2,4-triazole-1-yl) the methyl]-N-tertiary butyl-5-methoxyl group-2-biphenyl sulphonyl ammonia
With reference to the preparation method of embodiment 5, get faint yellow oily thing, yield: 76.2%.
1HNMR(CDCl 3，300MHz)：δ(ppm)0.996(9H，s，t-Bu)，3.450(1H，s，NH)，3.862(3H，s，CH 3O)，6.766(1H，d，J＝2.7Hz，H-4)，6.944(1H，d，J＝9.0Hz，H-6)，7.335(each?1H，d，J＝8.1Hz，CH 2-Ar)，7.525(each?1H，d，J＝7.8Hz，CH 2-Ar)，7.997(1H，s，3H)，8.085(1H，d，J＝8.7Hz，H-3)，8.150(1H，s，4H).
Embodiment 18
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl group-2-biphenyl sulfonamide
With reference to the preparation method of embodiment 6, get faint yellow solid, yield:53.4%.
Embodiment 19
N-{4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-alkylsulfonyl } propionic acid amide
With reference to embodiment 7 preparing methods, get white solid.Yield: 30.2%.mp?181-185℃。
IR(film，cm -1)：3440，3113，3033，2353，2024，1706，1599，1477，1324，1146；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.972(3H，t，J＝7.5Hz， CH 3CH 2)，1.969(2H，q，J＝7.5，7.5Hz，CH 3 CH 2)，3.862(s，3H，CH 3O)，5.425(2H，s)，6.730(1H，d，J＝2.1Hz)，7.023(1H，dd，J＝2.7，6.3Hz)，7.209～7.304(4H，m)，7.950(1H，s)，8.225(1H，s)，8.248(1H，d，J＝3.9Hz)，8.669(1H，s)；ESI-MS，m/z：399.1[(M-H) -].
Embodiment 20
N-{4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-alkylsulfonyl } valeramide
With reference to embodiment 8 preparing methods, get white solid.Yield: 45.1%.mp?94-98℃。
IR(film，cm -1)：3417，3122，2959，2932，2871，2025，1715，1595，1130，1138；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.864(3H，t，J＝4.5Hz， CH 3CH 2)，1.195～1.219(m，2H，CH 3 CH 2)，1.414～1.463(m，2H，CH 2 CH 2CH 2)，1.941(3H，t，J＝7.2Hz，CH 2 CH 2CO)，3.864(3H，s，CH 3O)，5.429(2H，s)，6.732(1H，d，J＝2.4Hz)，7.023(1H，dd，J＝2.4，6.3Hz)，7.238～7.311(m，3H)，7.956(1H，s)，7.227(1H，s)，7.256(1H，s)，8.758(1H，s)；ESI-MS，m/z：427[(M-H) -].
Embodiment 21
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-sulfoamido ethyl formate
With reference to embodiment 10 preparing methods, get white solid.Yield: 27.3%.mp?155-158℃。
1HNMR(CDCl 3，300MHz)：δ(ppm)1.160(3H，t，J＝6.9Hz， CH 3CH 2)，3.869(s，3H，CH 3O)，4.068(2H，q，J＝7.2，7.2Hz，CH 3 CH 2CO)，5.433(2H，s)，6.744(1H，d，J＝1.5Hz)，6.003(1H，dd，J＝2.7，6.3Hz)，8.029(1H，s)，8.182(1H，d，J＝9.0Hz)，8.370(1H，s)；ESI-MS，m/z：415.1[(M-H) -].
Embodiment 22
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-sulfoamido t-butyl formate
With reference to embodiment 11 preparing methods, get white solid.Yield: 23.4%.mp?94-96℃。
IR(film，cm -1)：3368，3129，2973，2024，1744，1592，1317，1156；
1HNMR(CDCl 3，300MHz)：δ(ppm)1.235(9H，s，t-Bu)，1.798(2H，s)，3.862(3H，s)，5.425(2H，s)，6.788(1H，s)，6.961(1H，d，J＝8.7Hz)，7.325(2H，d，J＝7.8Hz)，7.486(2H，d，J＝7.2Hz)，7.997(1H，s)，8.070(1H，d，J＝9.0Hz)，8.198(1H，s)；ESI-MS，m/z：443.2[(M-H) -].
Embodiment 23
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-sulfoamido butyl formate
With reference to embodiment 12 preparing methods, get white solid.Yield: 34.1%.mp?108-110℃。
IR(film，cm -1)：3482，3120，2959，2933，2025，1751，1512，1331；
1HNMR(CDCl 3，300MHz)：δ(ppm)0.900(3H，t，J＝9.3Hz)，1.192～1.257(2H，m)，1.447～1.541(2H，m)，3.871(3H，s，CH 3O)，4.052(2H，t，J＝6.6Hz，CH 2 CH 2O)，5.408(2H，s)，6.760(2H，d，J＝2.7Hz)，7.0127(2H，dd，J＝2.4，6.3Hz)，7.248(1H，s)，7.268(2H，d，J＝3Hz)，7.348(2H，d，J＝8.1Hz)，7.507(1H，s)，7.981(1H，s)，8.161(1H，s)，8.203(2H，d，J＝9.0Hz)；ESI-MS，m/z：443.1[(M-H) -].
Embodiment 24
4 '-[(1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-sulfoamido benzyl formate
With reference to the preparation method of embodiment 13, get white solid.Yield 37.2%.mp?164-167℃。
IR(film，cm -1)：3437，3032，2941，2024，1748，1593；
1HNMR(CDCl 3，300MHz)：δ(ppm)2.429(3H，s，CH 3O)，5.017(2H，s，CH 2O)，5.265(2H，s)，7.014(1H，s)，7.158～7.183(m，4H)，7.260～7.320(m，5H)，7.867(1H，s)，8.050(1H，s)，8.128(1H，d，J＝8.1Hz)；ESI-MS，m/z：477.2[(M-H) -].
Embodiment 25
4 '-[(5-bromo-1H-1,2,4-triazole-1-yl) the methyl]-N-tertiary butyl-5-methyl-2-biphenyl sulphonyl ammonia
With 4 '-[(1H-1,2,4-triazole-1-yl) methyl]-(0.285g 0.742mmol) is dissolved in CHCl to 5-isobutyl--2-sulphonyl ammonia 3(10ml), add successively NBS (0.138g 0.779mmol) and AIBN (catalytic amount), stirs, and it is intact to raw material reaction that temperature rising reflux reacts, suction filtration, concentrating under reduced pressure, acetic acid ethyl dissolution, washing, anhydrous sodium sulfate drying spends the night, column chromatography (CH 2Cl 2: CH 3OH=60: 1) get 0.135g oily matter.Yield: 38.3%.
1HNMR(CDCl 3，300MHz)：6(ppm)0.971(9H，s，t-Bu)，2.419(3H，s，CH 3)，3.459(1H，s，NH)，5.420(2H，s，CH 2)，7.085(1H，s，H-4)，7.287(1H，d，J＝8.1Hz，H-6)，7.358(each?1H，d，J＝8.1Hz，CH 2-Ar)，7.516(each?1H，d，J＝8.1Hz，CH 2-Ar)，7.935(1H，s，3H)，8.035(1H，d，J＝8.1Hz，H-3).
Embodiment 26
4 '-[(5-bromo-1H-1,2,4-triazole-1-yl) methyl]-5-methyl diphenyl-2-sulphonyl ammonia butyl formate
With reference to embodiment 11 preparing methods, get faint yellow solid.Yield: 30.5%.mp?89-91℃。
1HNMR(CDCl 3，300MHz)：δ(ppm)0.914(3H，t，J＝7.8Hz，CH 3)，1.146(2H，m，CH 2)，1.408(2H，m，CH 2)，2.433(1H，s，CH 3)，4.012(2H，t，CH 2O)，5.383(2H，s)，7.013(1H，s)，7.094(1H，s)，7.264～7.364(m，5H)，7.911(1H，s)，8.138(1H，d，J＝8.2Hz).
ESI-MS，m/z：509[(M+H) +]，M：[M+2]＝1∶1.
Embodiment 27
4 '-[(5-bromo-1H-1,2,4-triazole-1-yl) methyl]-5-isobutyl-biphenyl-2-sulphonyl ammonia butyl formate
With reference to embodiment 11 preparing methods, get faint yellow oily thing.Yield: 28.9%.
1HNMR(CDCl 3，300MHz)：δ(ppm)0.762(3H，t，J＝7.4Hz，CH 3)，0.848(6H，d，J＝6.5Hz)，1.335～1.350(2H，m，CH 3 CH 2)，1.809～2.022(1H，m)，2.486(2H，d，J＝7.1Hz， CH 2CH)，3.956(2H，t，J＝6.7Hz，CH 2O)，5.342(s，2H)，6.997(1H，s)，7.134(1H，s)，7.234～7.279(5H，m)，7.916(1H，s)，8.131(1H，d，J＝3.9Hz)；
ESI-MS，m/z：547[(M-H) -]，M：[M+2]＝1∶1.
Embodiment 28
4 '-[(5-bromo-1H-1,2,4-triazole-1-yl) methyl]-5-methoxyl biphenyl-2-sulphonyl ammonia butyl formate
With reference to embodiment 11 preparing methods, get faint yellow oily thing.Yield: 31.6%.mp?49-51℃。
1HNMR(CDCl 3，300MHz)：δ(ppm)1.485(2H，m)，1.751(2H，s)，3.866(3H，s，CH 3)，4.012(2H，t，J＝4.5Hz)，5.413(2H，s)，6.760(1H，s)，6.851(1H，s)，6.995(1H，d，J＝6.6Hz)，7.921(1H，s)，8.193(1H，d，J＝4.5Hz)；
ESI-MS，m/z：521[(M-H) -]，M：[M+2]＝1∶1.
Embodiment 29
Figure BSA00000511130100131
Get above-mentioned prescription, in flakes with the ordinary method preparation.

Claims (10)

1.通式(I)的化合物或其可药用盐：1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof: 其中R1代表氢、烷氧基、羧基、烷氧羰基、酯基；Wherein R represents hydrogen, alkoxy, carboxyl, alkoxycarbonyl, ester group; R2代表氢、C1-C6直链或支链的烷基、C2-C6直链或支链的链烯基、C2-C6直链或支链的炔基、C1-C6直链或支链的烷氧基、苯基、芳杂环或者取代芳杂环，所述取代芳杂基可任选自一个或多个选自C1-C6烷基、C1-C6烷氧基或卤素取代的芳杂基，各取代基相同或者不同；R 2 represents hydrogen, C 1 -C 6 straight or branched alkyl, C 2 -C 6 straight or branched alkenyl, C 2 -C 6 straight or branched alkynyl, C 1 -C 6 straight chain or branched alkoxy, phenyl, aromatic heterocycle or substituted aromatic heterocycle, the substituted aromatic heterocycle can be selected from one or more selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy or halogen substituted heteroaryl, each substituent is the same or different; R3代表氢、C1-C4的烷基或卤素；R 3 represents hydrogen, C 1 -C 4 alkyl or halogen; R4代表氢、C1-C4的烷基或烷氧基；R 4 represents hydrogen, C 1 -C 4 alkyl or alkoxy; Ar代表苯环或者芳杂环，所述芳杂环指1-2个杂原子的5-6元芳杂环，所述杂原子各自独立的选自O、S或N；。Ar represents a benzene ring or an aromatic heterocycle, and the aromatic heterocycle refers to a 5-6 membered aromatic heterocycle with 1-2 heteroatoms, each of which is independently selected from O, S or N; 2.权利要求1的化合物或其可药用盐，其中R1为氢、烷氧羰基或羰基。2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, alkoxycarbonyl or carbonyl. 3.权利要求1的化合物或其可药用盐，其中R2为氢、C1-C6直链或支链的烷基、C1-C6直链或支链的烷氧基。3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, C 1 -C 6 linear or branched alkyl, C 1 -C 6 linear or branched alkoxy. 4.权利要求3的化合物或其可药用盐，其中R2为C1-C4直链烷基或C1-C4直链烷氧基。4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein R 2 is C 1 -C 4 linear alkyl or C 1 -C 4 linear alkoxy. 5.权利要求4的化合物或其可药用盐，其中R2为甲基、异丁基或甲氧基。5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl, isobutyl or methoxy. 6.权利要求1的化合物或其可药用盐，其中R3为氢或卤素。6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen or halogen. 7.权利要求1的化合物或其可药用盐，其中R4为氢或烷基。7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen or alkyl. 8.权利要求1的化合物或其可药用盐，其中Ar为苯环、吡咯环或噻吩环。8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar is a benzene ring, a pyrrole ring or a thiophene ring. 9.一种用于治疗哺乳动物，优选于治疗人类疾病或病症的药物组合物，其包括治疗高血压、充血性心衰、心肌肥厚、血管痉挛和通过激动AT2受体来治疗其它疾病或病症的有效量的权利要求1的化合物或其盐和可药用载体。9. A pharmaceutical composition for treating mammals, preferably treating human diseases or conditions, including treating hypertension, congestive heart failure, cardiac hypertrophy, vasospasm and treating other diseases or diseases by stimulating AT2 receptors An effective amount of the compound of claim 1 or a salt thereof and a pharmaceutically acceptable carrier. 10.权利要求1的化合物或其盐在制备治疗高血压、充血性心衰、心肌肥厚、血管痉挛以及通过激动AT2受体来治疗其它病症的药物中的应用。10. The application of the compound or salt thereof according to claim 1 in the preparation of medicines for treating hypertension, congestive heart failure, cardiac hypertrophy, vasospasm and other diseases by activating AT2 receptors.
CN2011101500699A 2011-06-07 2011-06-07 Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof Pending CN102816126A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101500699A CN102816126A (en) 2011-06-07 2011-06-07 Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101500699A CN102816126A (en) 2011-06-07 2011-06-07 Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof

Publications (1)

Publication Number Publication Date
CN102816126A true CN102816126A (en) 2012-12-12

Family

ID=47300620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101500699A Pending CN102816126A (en) 2011-06-07 2011-06-07 Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof

Country Status (1)

Country Link
CN (1) CN102816126A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407733B2 (en) 2016-06-29 2022-08-09 Bristol-Myers Squibb Company Biarylmethyl heterocycles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1062289A (en) * 1990-11-17 1992-07-01 赫彻斯特股份公司 The treatment heart, blood vessel hypertrophy and outgrowth method
CN1192696A (en) * 1995-06-07 1998-09-09 G·D·瑟尔公司 Combination therapy of spironolactone and angiotensin Ⅱ antagonists for the treatment of congestive heart failure
CN1529697A (en) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ Tricyclic compounds useful as angiotensin II agonists
CN1544418A (en) * 2003-11-26 2004-11-10 中国药科大学 N-aryl-substituted-1H-pyrrole derivatives with cardiovascular activity
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1062289A (en) * 1990-11-17 1992-07-01 赫彻斯特股份公司 The treatment heart, blood vessel hypertrophy and outgrowth method
CN1192696A (en) * 1995-06-07 1998-09-09 G·D·瑟尔公司 Combination therapy of spironolactone and angiotensin Ⅱ antagonists for the treatment of congestive heart failure
CN1529697A (en) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ Tricyclic compounds useful as angiotensin II agonists
CN1544418A (en) * 2003-11-26 2004-11-10 中国药科大学 N-aryl-substituted-1H-pyrrole derivatives with cardiovascular activity
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘琴等: "选择性AT_2受体激动剂的构效关系研究进展", 《药学进展》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407733B2 (en) 2016-06-29 2022-08-09 Bristol-Myers Squibb Company Biarylmethyl heterocycles
US12037324B2 (en) 2016-06-29 2024-07-16 Bristol-Myers Squibb Company Biarylmethyl heterocycles

Similar Documents

Publication Publication Date Title
EP2432776B1 (en) Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
CN104016980B (en) For treating the benzamide compound of dysbolismus
ZA200106584B (en) Triazole compounds with dopamine-D3-receptor affinity.
CA2657260A1 (en) 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
CN103601670B (en) The similar thing of piperlongumine and its preparation method and application
TW201116280A (en) Azetidinyl diamides as monoacylglycerol lipase inhibitors
JPWO2010007944A1 (en) Nitrogenous bicyclic heterocyclic compounds
BR112017009012B1 (en) BENZO RING DERIVATIVES OF SIX LIMBS AS A DPP-4 INHIBITOR AND USE THEREOF
CN103102352B (en) Tyrosine kinase inhibitor indolinone derivative
CN103562191A (en) Nitrogen-containing saturated heterocyclic compound
CN111423432B (en) (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof
CA3012812A1 (en) Heterocyclic sulfonamide derivative and medicine containing same
CN106957242A (en) A kind of schiff base compounds and preparation method thereof and pharmaceutical applications
JP6236083B2 (en) Bicyclic heteroarylcycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinase (SYK)
WO2007036131A1 (en) Carzole sulphamide derivatives and their preparation method
CN107721919A (en) Phenylchinoline class TRPV1 antagonists and its preparation method and application
CN115353508A (en) 5-pyridine-1H-indazole compound, pharmaceutical composition and application
CN104804001B (en) 4 substituted azoles simultaneously [2,3 d] pyrimidine compound and application thereof
CN102816126A (en) Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof
CN115304583A (en) 5-Pyridine-1H-indazoles targeting CLK2 and their applications
CN104016936B (en) The application in efavirenz asymmetric synthesis of the chiral aminophenol part
JP5745501B2 (en) Benzanilide derivatives
CN110105286B (en) Substituted heterocyclic compound containing urea skeleton and preparation method and application thereof
CN102775371B (en) Substituted thiadiazine derivatives, as well as preparation method and application thereof
ES2710020T3 (en) Pyrazole compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212